Biotech investors, mark your calendars and update your watch lists with the dates and companies in this report. Major catalysts are coming down the pike for these companies in the form of FDA decisions and reports of clinical trial data. I have put together a list of companies ranging from around $100 million to just over $1 billion in market cap that are expected to be on the move within the next nine months. Some are well known and heavily traded, while others may be new to you and worthy of further investigation.
The Fool's CAPS community is not optimistic about Neurochem's prospects. The stock has a lowly one-star rating and bears outnumber the bulls by a two-to-one margin.
Keep in mind this is not meant to be an exhaustive list of all companies in the sector, and I purposely excluded the biggest and most well-known biotech and big pharma companies. My goal is to provide a small selection of companies with a combination of leverage because of their smaller size and a major upcoming catalyst in the way of clinical trial data or FDA decision deadlines. Those two factors can lead to big moves in share prices, which makes these companies worth watching.
Looking for more Foolish biotech coverage? Check out the Fool's market-beating Rule Breakers newsletter. You can check out all our recommendations and get access to our message boards and exclusive content with a 30-day free trial.
Fool contributor Mike Havrilla, R.Ph., B.S., Pharm.D., is a Rite Aid pharmacist who lives and works in the small Pennsylvania town of Portage. He invites your comments and feedback. Mike does not have a position in any company mentioned here. The Fool has a disclosure policy.